Epiberberine Options
Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the primary-line therapy of CML-CP. Five hundred and nineteen patients with recently diagnosed CML-CP had been randomly assigned to get dasatinib at a dose of a hundred mg when everyday (259 patients) or imatinib in a dose of 400 mg the moment everyd